. Down-modulation of CD4 seems to be via clathrin-dependent endocytosis, whereas down-modulation of MHC class I remains unexplained. Several mutant proteins, including mutations in the small GTPase Arf6, have been used to probe membrane traffic pathways. One such mutant has recently been used to propose that Nef acts through Arf6 to activate the endocytosis of MHC class I. Here, we show that MHC class I down-modulation is unaffected by other Arf6 mutants that provide more specific perturbations in the GDP-GTP cycling of Arf6. Inhibition of phosphatidylinositol-3-phosphate kinase, an upstream activator of Arf6, also had no effect on the internalization step, but its activity is required to direct MHC class I to the trans-Golgi network. We conclude that the apparent Arf6 dependency of Nef-mediated MHC class I down-modulation is due to nonspecific perturbations in membrane traffic.
INTRODUCTION
One strategy used by HIV virus to evade immune recognition of infected cells is to down-modulate the expression of major histocompatibility complex (MHC) class I at the plasma membrane by the expression of the viral protein Nef (Schwartz et al., 1996; Collins et al., 1998; Cohen et al., 1999) . Nef also induces the down-modulation of other membrane proteins such as CD4 and CD28 (Greenberg et al., 1998a; Swigut et al., 2000 Swigut et al., , 2001 . Nef has three recognized interaction motifs involved in membrane traffic, one is a dileucinebased sequence that interacts with clathrin adaptors (Bresnahan et al., 1998; Greenberg et al., 1998a) , a second is a PxxPbased sequence that interacts with src homology (SH)3 domains (Saksela et al., 1995; Grzesiek et al., 1996; Lee et al., 1996; Arold et al., 1997; Fackler et al., 1999) , and a third is a EEEE-based sequence that interacts with the phosphofurin acidic cluster sorting 1 protein (PACS-1) (Piguet et al., 2000; Crump et al., 2001) . The first of these is unnecessary for MHC-I down-regulation, but both the SH3 motif and the PACS-1 interaction motif are required. CD4 down-modulation is relatively well understood; it involves the association of both Nef and CD4 with the clathrin adaptor AP-2 and the subsequent incorporation of the entire complex into clathrin-coated vesicles (Bresnahan et al., 1998; Greenberg et al., 1998a,b) . Down-modulation of MHC-I, in contrast, does not require the interaction of Nef with AP-2 (Greenberg et al., 1998a; Mangasarian et al., 1999) . Blockage of the clathrin endocytic pathway by overexpression of a dynamin mutant prevents Nef-mediated CD4 but not MHC-I down-modulation (Le Gall et al., 2000) , even though MHC-I can be found in endocytic clathrin-coated vesicles in the absence of Nef (Machy et al., 1987) .
The activity of the small GTPase Arf6 may be involved in Nef-dependent MHC-I internalization (Blagoveshchenskaya et al., 2002) . This idea initially arose from the fact that MHC-I, in the absence of Nef, is found in a vesiculo-tubular network involved in a form of clathrin-independent endocytic traffic between the plasma membrane and endosomal compartments (Radhakrishna and Donaldson, 1997; Brown et al., 2001; Caplan et al., 2002; Naslavsky et al., 2003) . The integrity of this pathway requires the function of Arf6 (Radhakrishna and Donaldson, 1997; Brown et al., 2001; Caplan et al., 2002; Naslavsky et al., 2003) . Recently, it was shown that overexpression of the constitutively active Arf6Q67L, which lacks GTPase activity, blocks Nef-mediated MHC-I down-modulation (Blagoveshchenskaya et al., 2002) . This observation led to the suggestion that the Nef-mediated traffic of MHC-I also involves the Arf6 vesiculo-tubular network. Further observations by Blagoveshchenskaya et al. (2002) led them to propose that targeting of Nef to the endosome/trans-Golgi network (TGN) compartment activates phosphatidylinositol-3-kinase (PI-3-kinase), which activates the guanine nucleotide exchange factor (GEF) ARNO, which in turn activates Arf6 at the plasma membrane. These events culminate in increased MHC-I internalization.
The Arf6 mutant used in this study, Arf6Q67L, has a specific defect in GTPase activity and therefore is trapped in the GTP form. As a result, GTP-activating factors (GAPs) specific for Arf6 are trapped in complex with the mutant Arf and are unavailable to endogenous Arf6, which therefore is locked in its active state. If the model suggested by Blagoveshchenskaya et al. (2002) is correct, other mutations affecting nucleotide cycling in Arf6 should modulate the effects of Nef-induced PI-3-kinase activation as well.
We therefore set out to test whether other Arf6 mutants have the predicted effect on MHC-I down-modulation. We confirmed that the constitutively active Arf6Q67L blocks MHC-I down-modulation. Surprisingly, the dominant negative Arf6T27N, which is defective in GTP loading and therefore remains complexed with GTP exchange factors, had no effect on MHC-I down-modulation. Furthermore, expression of the "fast-cycling" Arf6T157A, which does not require GEF to exchange GDP for GTP, did not enhance or substitute for the effects of Nef on MHC-I internalization (Santy, 2002) . These and other results suggest that the effects of Nef are unlinked to the GDP-GTP cycling of Arf6. The effect of Arf6Q67L on Nef function may be a consequence of global perturbations in the organization of the traffic system used by MHC-I rather than a specific interaction between Arf6 and Nef. Moreover, we found that the inhibition of PI-3-kinase had no effect on the Nef-mediated uptake of MHC-I from the cell surface, although it does prevent the traffic of internalized MHC-I from endosomes to the TGN, in accordance with previous results (Swann et al., 2001) showing that the activity of PI-3-kinase is required for retention of MHC-I in the Golgi compartment of cells expressing Nef.
MATERIALS AND METHODS

Reagents
Jurkat T cells expressing high levels of human CD4 (a kind gift from Dr. Dan R. Littman, New York University, New York, NY) were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum along with 2 mM lglutamine, penicillin (50 U/ml), and streptomycin (50 mg/ml). U373 mg astrocytoma cells (generously provided by Drs. Domenico Tortorella and Hidde Ploegh, Harvard Medical School, Boston, MA) and human embryonic kidney 293T cells (a kind gift from Dr. Rick van Etten, Harvard Medical School) were grown in DMEM medium supplemented with 10% fetal bovine serum, 2 mM l-glutamine, penicillin (50 U/ml), streptomycin (50 mg/ml), and nonessential amino acids (0.1 mM). A purified mouse monoclonal antibody (W6/32, hereby referred to anti-MHC-I), which recognizes assembled MHC-I heavy chain-␤2 microglobulin complexes, harvested from hybridoma cells (a kind gift from Dr. Hidde Ploegh, Harvard Medical School), was fluorescently labeled with Alexa Fluor 594 fluorophores (A594-anti-MHC-I) following instructions of the manufacturer (Molecular Probes, Eugene, OR). A purified monoclonal anti-␤1-integrin antibody was kindly provided by Drs. Junichi Takagi and Timothy A. Springer (Harvard Medical School). Monoclonal HA-antibody, 12CA5, was harvested from hybridoma cells. Plasmids containing HA-tagged Arf6 (wild type, T27N, and Q67L) were kindly provided by Drs. Julie Donaldson (National Institutes of Health, Bethesda, MD), and Michel Franco (Institut dePharmacologie Moleculaire, CNRS, Valbonne, France). Plasmid containing Eps15(⌬95-295) fused to enhanced green fluorescent protein (EGFP) was kindly provided by Dr. Jennifer LippincottSchwartz (National Institutes of Health). The EHD1 cDNA (a kind gift from Dr. Mia Horowitz, Tel Aviv University, Tel Aviv, Israel) was fused with EGFP in the pEGFP-C1 vector (BD Biosciences Clontech, Palo Alto, CA). The monomeric red fluorescent protein (mRFP) (Campbell et al., 2002) , generously provided by Dr. Roger Y. Tsien (University of California, San Diego, La Jolla, CA), was fused with NefAAAA in the MIGR1 vector. Wortmannin (SigmaAldrich, St. Louis, MO) was dissolved in dimethyl sulfoxide (DMSO) according to manufacturer's recommendations. FuGENE 6 (Roche Diagnostics, Indianapolis, IN) was used for plasmid transfections.
Mutagenesis, Retroviral Vector Constructs, Virus Preparation, and Transductions
All mutations in Nef (strain NL4-3) and Arf6 cDNAs were introduced using the QuikChange protocol (Stratagene, La Jolla, CA) and subsequently confirmed by DNA sequencing. The following mutants were generated: a form of Nef in which the methionine at position 20 was changed to alanine (NefM20A), a form of Nef in which the proline-rich P 72 xxP 75 (x is any amino acid) motif was changed to A 72 xxA 75 (NefAxxA), a mutant in which the acidic stretch ) was substituted with a quadruple alanine stretch (NefAAAA), a fast-cycling mutant of Arf6, Arf6T157A (Santy, 2002) and a variant of the constitutively active Arf6Q67L, referred to as Arf6N48I;Q67L, which is incapable of activating the downstream effector phospholipase D (PLD) (Vitale et al., 2002) .The bicistronic retroviral vector MIGR1 (Pear et al., 1998) was modified to contain either a single cDNA encoding Nef fused to EGFP or two separate open reading frames, i.e., Arf6-HA and Nef-EGFP, placed upstream and downstream of an internal ribosomal entry sequence (IRES) ( Figure 1A ). Flow cytometry and fluorescence imaging confirmed levels of Arf6-hemagglutinin (HA) and Nef-EGFP. Recombinant virus was produced by simultaneous transient three-plasmid transfection of the 293T tumor cell line with the MIGR1-based constructs, a pMD.MLV vector containing murine stem cell virus Gag and Pol genes, and the pMD.G vector containing the vesicular stomatitis virus envelope gene (Pear et al., 1993; Soneoka et al., 1995) . Retroviral-containing supernatants were collected 36 -40 h after transfection and used immediately for transduction of Jurkat T cells (twofold dilution) or U373 mg astrocytoma cells (fivefold dilution) in the presence of 4 g/l polybrene (Sigma-Aldrich).
Flow Cytometric Analysis of MHC-I, CD4, and EGFP Expression
Flow cytometric analysis (FACSCalibur flow cytometer; BD Biosciences, Franklin Lakes, NJ) for the surface expression of CD4 or MHC-I and the total cellular content of the appropriate fusion proteins containing EGFP were performed in Jurkat T cells (25,000/sample). Aliquots of 25,000 cells were washed in 1% bovine serum albumin/PBS and stained for 30 min on ice with diluted mouse monoclonal anti-CD4 antibody conjugated to phycoerythrin (BD PharMingen, San Diego, CA) and mouse monoclonal anti-HLA-A,B,C antibody conjugated to allophycocyanin (BD PharMingen). Excess antibody was removed by five washes with 1% bovine serum albumin/PBS and then fixed for 15min on ice with 3% paraformaldehyde in PBS. The rate of MHC-I internalization was determined at least three times by following the uptake of the mouse monoclonal Alexa594-anti-MHC-I as described previously (Swigut et al., 2000) . The role of PI-3-kinase on MHC-I internalization was determined in Jurkat T cells preincubated for 1h at 37°C with wortmannin (1 or 5 M) or DMSO (control), followed by its presence during the antibody internalization assay.
Optical Microscopy
Fluorescent images were acquired with a fully motorized and computer driven inverted wide-field epifluorescence/confocal microscope (Axiovert 200M; Carl Zeiss, Thornwood, NY) equipped with a spinning-wheel confocal head (Applied Biosystems, Foster City, CA). Image acquisitions, three-dimensional restoration and analysis were done with the aid of SlideBook (Intelligent Imaging Innovations, Denver, CO) as described previously (LegesseMiller et al., 2003) .
The astrocytoma cells were seeded at ϳ40 -50% confluence on 18-or 25-mm coverslips 24 h before transfection or transduction, and imaging experiments were performed typically 48 -72 h after. The uptake of cell surface MHC-I molecules was followed at 37°C by monitoring the location of internalized A594-anti-MHC-I antibodies diluted in HMEMB medium added to live cells. In the case of Jurkat T cells, experiments were done with the cells in suspension, which were later sedimented on poly-lysine-coated coverslips by centrifugation at 900 ϫ g for 5min. Cells were then washed with PBS ϩϩ (containing 0.1 mM CaCl 2 and 1 mM MgCl 2 ), fixed with 3% paraformaldehyde for 10 min at room temperature, and imaged. The steady-state distribution of MHC-I was determined after fixation, by incubation of the cells for 2 h at room temperature with A594-anti-MHC-I antibodies diluted in HMEMB medium with 0.2% saponin.
RESULTS
Validation of the Expression System
Because most methods of transient protein expression are not very efficient, particularly when using Jurkat T cells, we implemented a retroviral-based bicistronic vector MIGR1 ( Figure 1A ) for protein expression that routinely allows transduction efficiencies of 95-100% in Jurkat T cells and U373 mg astrocytoma cells ( Figure 1B ). We first verified that expression of Nef (strain NL4-3) yielded the expected effects on MHC-I and CD4 down-modulation. As shown in Figure  1B , expression of the chimeric Nef protein (Nef fused at its carboxy terminus to EGFP) for 2 d in Jurkat T cells induced substantial surface down-modulation of MHC-I and CD4. As demonstrated earlier, this effect directly correlates with the expression levels of Nef alone or Nef fused to EGFP (Greenberg et al., 1998b; Swigut et al., 2000; Liu et al., 2001) . The down-modulation of MHC-I involves a fourfold increase in its rate of internalization ( Figure 1C) , well within the range obtained by others using transiently transfected Jurkat or HeLa cells (Swigut et al., 2000; Blagoveshchenskaya et al., 2002) . As expected from previous work (Greenberg et al., 1998b; Mangasarian et al., 1999; Akari et al., 2000; Piguet et al., 2000; Blagoveshchenskaya et al., 2002) , expression of NefM20A, NefAxxA, or NefAAAA induced a robust downmodulation in the surface expression of CD4, but not of MHC-I ( Figure 1B) . Similarly, direct visualization of surface MHC-I and its uptake (monitored by following the internalization of Alexa594-anti-MHC-I, a fluorescently labeled antibody specific for the ectodomain of MHC-I) in astrocytoma cells expressing Nef-EGFP showed the expected decrease in surface expression of MHC-I and the accumulation of internalized MHC-I in the perinuclear region within transferrincontaining endosomes ( Figure 1D) , and in the TGN (see below; Figure 5C ) together with the decrease in the total pool of MHC-I (our unpublished data). As expected, expression of NefM20A, NefAxxA, or NefAAAA in astrocytoma cells had no influence in the traffic of MHC-I. Together, these results validate the use of the viral vector as an efficient system for protein expression in Jurkat and astrocytoma cells.
Nef and the Intracellular Traffic of MHC-I
To follow the internalization pathways of MHC-I in more detail, we incubated the astrocytoma cells with the MHC-I antibody in the absence or presence of Nef. In the absence of Nef, a fraction of the anti-MHC-I antibodies labeled the cell periphery, including colocalization with clathrin and its endocytic adaptor AP-2, whereas another fraction was internalized into an early endosomal compartment. The early endosome compartment was identified by being labeled with the early endosomal marker EEA1 (Figure 2A) , and by containing fluorescent transferrin taken up by clathrin-dependent receptor-mediated endocytosis (our unpublished data). A similar distribution of MHC-I was observed in cells expressing the Nef mutants NefM20A, NefAxxA, or Nef AAAA, which do not induce MHC-I down-modulation (our unpublished data). These observations confirm previous suggestions from electron microscopy (Machy et al., 1987) that in the absence of Nef MHC-I can be internalized via the clathrin-dependent pathway.
In the presence of Nef, however, internalized MHC-I trafficked not only to transferrin-containing endosomes but also reached the TGN (see below; Figure 5C ). It is known that the surface down-modulation of MHC-I does not require a clathrin-dependent pathway (Greenberg et al., 1998a; Le Gall et al., 2000) . Confirming this, overexpression of the dominant negative Eps15⌬95-295 form of Eps15, a specific inhibitor for the clathrin endocytic pathway (Benmerah et al., 1999) , had no effect on the Nef-induced down-modulation of MHC-I ( Figure 2B ). In the absence of Nef, a small fraction of cells (1-5%) displayed a vesiculo-tubular network containing internalized MHC-I antibody (Figure 3) . The frequency of this phenotype was similar in astrocytoma cells expressing wildtype Nef, NefM20A, or NefAxxA. Unexpectedly, the expression of NefAAAA results in a substantial increase (10 -20%) in the number of cells displaying the vesiculo-tubular network. Similar expansion of the tubular network was observed with Jurkat T cells ( Figure 3C ). The tubules observed in the astrocytoma cells expressing NefAAAA were long (20 -60 m) and thin (Ͻ0.5 m), and formed as bundles, some linking the perinuclear compartment with the plasma membrane, some emanating from the plasma membrane, and others from the endosomal compartment ( Figure 3A) . Most tubes aligned with microtubules ( Figure 3B ), and their existence was abolished by incubation of the cells with 10 M Nocodazole for 1 h (our unpublished data). Membranebound tubes have previously been observed in studies of membrane proteins including MHC-I and ␤1-integrins and are known to provide a clathrin-independent mode of traffic that is sensitive to the nucleotide status of Arf6 (Radhakrishna and Donaldson, 1997; Brown et al., 2001) . The tubes we observed contained all the predicted membrane proteins including EHD1, an important regulator of Arf6-regulated membrane recycling (Caplan et al., 2002; Galperin et al., 2002) , but not transferrin ( Figure 3A) , and tube formation was blocked by coexpression of wild-type Arf6, Arf6Q67L, or Arf6T157A.
Arf6 Is Not Directly Involved in the Nef-mediated DownModulation of MHC-I
It has been proposed that the Arf6-regulated membrane trafficking pathway is responsible for the increased downmodulation of MHC-I in response to Nef (Blagoveshchenskaya et al., 2002) . This model rests in part on the observation that Nef-dependent down-modulation of MHC-I, but not CD4, is blocked by expression of Arf6Q67L, a form of Arf6 that remains in the active state by poorly hydrolyzing GTP (D' Souza-Schorey et al., 1995) , which disrupts the vesiculotubular network (Radhakrishna and Donaldson, 1997) . We therefore examined the effects of Arf6T27N, a form of Arf6 that is unable to exchange GDP for GTP and that, by scavenging the available GEF, acts as a dominant negative mutant for the traffic through the vesiculo-tubular network (Radhakrishna and Donaldson, 1997) . As shown in Figure 4 , A and B, expression of Arf6T27N in Jurkat and astrocytoma cells at levels similar to those of Arf6Q67L had no detectable effect on MHC-I down-modulation in response to Nef. It also had no effect on the rate of internalization of MHC-I in Jurkat T cells in the presence of Nef ( Figure 4C ). Next, we tested the effect of Arf6T157A, a fast-cycling form of Arf6 that undergoes spontaneous GDP-GTP exchange (Santy, 2002) . If the model is correct, expression of Arf6T157A should mimic the effect of Nef on MHC-I internalization. We saw no effect of Arf6T157A on MHC-I traffic, either in the presence or absence of Nef (Figure 4 ; our unpublished data). Finally, it is known that Arf6N48I fails to activate at least one of its known downstream effectors, PLD, whereas it still activates PI4P5-kinase (Jones et al., 1999; Skippen et al., 2002) and interacts normally with its own GEFs and GAPs showing no impairment in GTP loading and hydrolysis (Vitale et al., 2002) . Thus, we expressed Nef together with ArfN48I; Q67L, a form of Arf6 that should remain in the active state, but fail to activate PLD. As illustrated in Figure 4A , expression in Jurkat T cells of Arf6N48I;Q67L and Nef did not prevent the Nef-mediated surface down-modulation of MHC-I, suggesting that the interference of Arf6Q67L on MHC-I traffic is not related to the GTP/GDP cycle of Arf6. As a control experiment, expression in astrocytoma cells of Arf6N48I;Q67L and Nef results in the appearance of the same type of small vacuoles and protrusions observed upon expression of Arf6Q67L and Nef (our unpublished data), consistent with the suggestion that Arf6N48I;Q67L is locked in the active state.
Activity of PI-3-Kinase Is Required for the Nef-mediated MHC-I Retention in TGN
Although it seems that the GTP cycle of Arf6 is not important in regulating Nef-dependent MHC-I internalization, it is still possible that PI-3-kinase may be involved. Wortmannin is an inhibitor of p85/p110 PI-3-kinase that, at the concentrations used here (0.5-5 M), also inhibits the related VPS34 PI-3-kinase (reviewed in Siddhanta et al., 1998; Futter et al., 2001) , but is not known to affect the activity of any other kinases. Incubation with wortmannin for 2.5 h had no effect on the surface and intracellular levels of MHC-I in Nefexpressing astrocytoma cells ( Figure 5A ). We also found that wortmannin had no effect on the rate of internalization of MHC-I in Nef-expressing Jurkat cells ( Figure 5B ). This treatment did, however, clearly reduce the amount of MHC-I retained in or trafficked into the TGN in astrocytoma cells ( Figure 5C ) or Jurkat T cells (our unpublished data), even though the amount of MHC-I internalized into the endosomal compartment did not vary. These results indicate that wortmannin is active in our experiments and that PI-3-kinase has an important role in directing internalized MHC-I from endosomes to the TGN but does not influence the early stages of MHC-I traffic mediated by Nef.
DISCUSSION
Nef seems to modulate at least two independent endocytic pathways, a clathrin-dependent pathway, which is important for the down-modulation of CD4 (Greenberg et al., 1997; Bresnahan et al., 1998; Greenberg et al., 1998a ) and a clathrinindependent pathway, which is important for the downmodulation of MHC-I (Le Gall et al., 2000; Swann et al., 2001) . Different motifs on Nef are involved in these two functions; the clathrin-adaptor-binding motif is important for CD4 down-modulation (Greenberg et al., 1997 (Greenberg et al., , 1998a Bresnahan et al., 1998; Mangasarian et al., 1999) , whereas the SH3-and PACS-1-binding motifs and the methionine at position 20 are involved in MHC-I down-modulation (Greenberg et al., 1998b; Akari et al., 2000; Piguet et al., 2000; Crump et al., 2001; Blagoveshchenskaya et al., 2002) . Arf6 modulates membrane trafficking between the plasma membrane and a nonclathrin-derived endosomal compartment (Radhakrishna and Donaldson, 1997; Brown et al., 2001; Naslavsky et al., 2003) The observation that Arf6Q67L prevents the Nef-mediated down-modulation of MHC-I, but not of CD4, led to the conclusion that Nef modulates MHC-I traffic by affecting Arf6 activity (Blagoveshchenskaya et al., 2002) . Observations that an inhibitor of PI-3-kinase, LY294002, also inhibits MHC-I down-modulation allowed a further elaboration of the model to include upstream activation of PI-3-kinase by Figure 1A . The expression levels of Arf6 and its mutants were determined to be equivalent by Western blot analysis (our unpublished data). (B) Effect of selected Arf6 mutants in the rate of MHC-I internalization induced by Nef. The experiments were performed as described in Figure 1B Nef as the first step in the pathway leading to Arf6 activation.
In agreement with Blagoveshchenskaya et al. (2002) , we found that overexpression of Arf6Q67L completely blocked the down-modulation effects of Nef on MHC-I but not on CD4. When we examined other mutants, however, that should have similar or opposite effects to the Arf6Q67L mutant, we instead found no effect. The Arf6Q67L mutant poorly hydrolyzes GTP and remains bound to GTPase-activating proteins, preventing the GTP/GDP cycle required for Arf6 function. The Arf6T27N mutant is defective in GTP loading, thus scavenging all available Arf6GEFs and the Arf6T157A mutant is able to spontaneously load GTP, bypassing the requirement for Arf6GEF. Neither of these mutants inhibited or enhanced MHC-I internalization. Similarly, there was no effect on the down-modulation of MHC-I upon expression of Arf6T27N and Nef, although expression of the Arf6T27N mutant alone was shown to inhibit recycling of MHC-I in A7 melanoma cells (Blagoveshchenskaya et al., 2002) . Arf6 activates phospholipase D (Massenburg et al., 1994; Vitale et al., 2002) , an enzyme used in a number of membrane-budding events (Ktistakis et al., 1996; Shen et al., 2001) . It is particularly interesting that Arf6N48I;Q67L, a double mutant that is expected to remain in the active GTP state but fails to activate certain downstream effectors such as phospholipase D (Vitale et al., 2002) , does not inhibit MHC-I down-modulation. Because this double mutant should scavenge GAPs in the same way that Arf6Q67L does, it is hard to reconcile this result with the hypothesis that GTP cycling on Arf6 is required to down-modulate MHC-I. Expression of the Arf6T27N and Arf6Q67L mutants clearly interfere with Fc-mediated phagocytosis in macrophages and leukocyte migration (Weber et al., 2001) . The results from the use of these mutants make it clear that there is a direct link between the GDP-GTP cycling of Arf6 and the biological process under investigation. In contrast, we do not believe that a similar relationship has been established between Nef and Arf6.
How then, can one rationalize the inhibitory effect of Arf6Q67L in MHC-I traffic? Arf6Q67L has two main effects: it sequesters GAPs, causing the endogenous Arf6 proteins to remain in the active form for longer, and it causes chronic activation of all the downstream effectors of Arf6. We suggest that the combined disruptions resulting from Arf6Q67L expression, GAP sequestration and activation of downstream effectors, causes nonspecific perturbations in membrane traffic that are not related to the GTP/GDP cycle of Arf6. We argue that the use of this mutant alone should not be thought of as sufficient evidence to identify processes that depend on Arf6 activity.
What role does PI-3-kinase play in MHC-I traffic? Blagoveshchenskaya et al. (2002) found that Nef stimulated the GTP loading of Arf6 and that this stimulation was blocked by addition of LY294002, a PI-3-kinase inhibitor that also blocks MHC-I down-modulation in response to Nef. The NefAxxA mutant, which lacks the SH3-binding motif, does not induce MHC-I down-modulation, but a chimeric protein in which NefAxxA is fused to the catalytic subunit of PI-3-kinase (p110) does. Together, these results seemed to support a model in which Nef recruits PI-3-kinase to the endosome/TGN, PI-3-kinase activates the GEF ARNO, and Arf6 becomes activated, resulting in increased MHC-I internalization (Blagoveshchenskaya et al., 2002) . Given that the Arf6 GTP/GDP cycle now seems not to be relevant to MHC-I internalization, it is possible that PI-3-kinase may be acting via some other mechanism, not relevant to Arf6. Although the Blagoveshchenskaya et al. (2002) chimeric Nef-PI-3-kinase experiment indicates that PI-3-kinase may be sufficient to induce MHC-I entry under some circumstances, our data showing that wortmannin does not inhibit MHC-I internalization indicate that PI-3-kinase is not required for the increase of MHC-I internalization mediated by wild-type Nef. This interpretation is consistent with observations by others showing that PI-3 kinase activity is not required for MHC-I uptake in the absence of Nef (Naslavsky et al., 2003) . PI-3-kinases do, however, play a role in membrane traffic involving the endosomal and Golgi compartments (Spiro et al., 1996; Lauvrak et al., 2002; Naslavsky et al., 2003) , particularly VPS34 that is involved in the regulation of membrane traffic between the Golgi and vacuoles/lysosomes (reviewed in DeCamilli et al., 1996; Herman et al., 1992; Sheperd et al., 1995) . We find that inhibition with 0.5-1 M wortmannin or with LY294002 (Swann et al., 2001 ) prevents retention of internalized MHC-I in the TGN, a step that is required for MHC-I down-modulation (Greenberg et al., 1998b; Piguet et al., 2000) . Because the same amount of wortmannin inhibits the enzymatic activity of p85/p110 or VPS34 (Siddhanta et al., 1998; Futter et al., 2001) , however, it is not possible to use this inhibitor to distinguish the relative contribution of these kinases to the traffic of MHC-I to the TGN. Intriguingly, expression of the NefAAAA mutant, which cannot interact with PACS-1, thereby preventing targeting and retention of MHC-I at the Golgi, nevertheless causes a dramatic increase in the Arf6 vesiculo-tubular network. We propose that this mutant could be useful to understand the functional relationships between Nef and Arf6. Further experiments will be required to test this possibility.
